Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Collagenase clostridium histolyticum - BioSpecifics Technologies Corporation/Endo, Inc.

Next Previous
X
Search
Drug Profile

Collagenase clostridium histolyticum - BioSpecifics Technologies Corporation/Endo, Inc.

Alternative Names: AA-4500; AK-160; CCH; Clostridial collagenase; Collagenase clostridium histolyticum-aaes; Cordase; EN-3835; PF-5076985; Plaquase; Qwo; XIAFLEX; Xiapex

Latest Information Update: 09 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioSpecifics Technologies Corporation
  • Developer Actelion Pharmaceuticals; Asahi Kasei; BioSpecifics Technologies Corporation; Endo International; Endo, Inc.; Swedish Orphan Biovitrum
  • Class Antineoplastics; Collagenases; Skin disorder therapies; Urologics
  • Mechanism of Action Collagenase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peyronie's disease; Dupuytren's contracture
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cellulite; Dupuytren's contracture; Peyronie's disease
  • Phase III Fibroma
  • Phase II Frozen shoulder; Lipoma; Plantar fasciitis
  • No development reported Breast disorders; Metabolic disorders; Uterine leiomyoma
  • Discontinued Hypertrophic scars; Keloids; Tendon injuries

Most Recent Events

  • 08 Aug 2024 Efficacy and adverse event data from a phase-II trial in Fibroma released by Endo International
  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 21 Mar 2024 Endo Pharmaceuticals completes a phase III trial in Fibroma in USA (Intralesional) (NCT05254457)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top